Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukocyte interleukin - CEL-SCI

Drug Profile

Leukocyte interleukin - CEL-SCI

Alternative Names: BC-IL; Buffy coat interleukins - CEL-SCI; Interleukin-2 cocktail - CEL-SCI; Leucocyte Interleukin injection - CEL-SCI; Multikine

Latest Information Update: 14 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; Ergomed; Naval Medical Research Center; Orient Europharma; Teva Pharmaceutical Industries
  • Class Antineoplastics; Granulocyte-macrophage colony-stimulating factors; Interferons; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • No development reported Cervical dysplasia; Condylomata acuminata
  • Discontinued Breast cancer; HIV infections; Prostate cancer

Most Recent Events

  • 08 Dec 2017 CEL-SCI completes the phase III IT-MATTERS trial in Head and neck cancer (First-line therapy, Neoadjuvant therapy) in in USA, Poland, India, Poland, Canada, Israel, Russia, Taiwan, Croatia, Hungary, Bosnia-Herzegovina, Serbia, Ukraine, Austria, United Kingdom, France, Sri Lanka, Turkey, Thailand, Italy, Spain, Malaysia, Romania, Belarus (Perilesional) (NCT01265849)
  • 07 Dec 2017 An Independent Data Monitoring Committee recommends continuation of a phase III trial in Head and neck cancer
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cervical-dysplasia in USA (Perilesional, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top